Blood plasma trial finds no benefit for severely ill patients
KATE KELLAND AN international trial testing convalescent blood plasma in cases of moderate and severe COVID-19 has halted enrolment of severely ill patients requiring intensive care after finding the plasma was of no benefit, trial investigators have said The decision by the REMAP-CAP trial leaders came after an initial analysis of more than 900 severely ill trial participants in intensive care showed that treatment with the product - an antibody-rich plasma taken from people who have recovered from the pandemic disease - did not improve outcomes. "There was no evidence of harm associated with the administration of convalescent plasma" (and)…